Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced it has received approval from the China State Food and Drug Administration to market ABRAXANE® Paclitaxel for Injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The Phase III clinical trials in the U.S.
More...